2021
Celularity and MaxCyte Sign Strategic Platform License to Advance Celularity’s Off-the-shelf Allogeneic Cellular Therapy Product Candidates
May 25, 2021
Read Full Release
Proposed Dual-Listing on Nasdaq
May 14, 2021
Read Full Release
MaxCyte to Participate in Two Upcoming Virtual Healthcare Investor Conferences
February 23, 2021
Read Full Release
Myeloid Therapeutics and MaxCyte Enter Clinical and Commercial Licensing Agreement to Advance Myeloid’s Cell Therapy Programs
January 11, 2021
Read Full Release
2020
CARMA Cell Therapies™ to Share Results of In-vitro Characterization of MCY-M11 at SITC 2020 Annual Meeting
November 9, 2020
Read Full Release
MaxCyte to Present at Two Upcoming Virtual Healthcare Investor Conferences
November 9, 2020
Read Full Release
MaxCyte Bolsters Leadership Team with Promotion of Brad Calvin to Chief Commercial Officer and New Key VP Appointments
October 13, 2020
Read Full Release
MaxCyte to Present at Upcoming 2020 H.C. Wainwright & Co 22nd Annual Global Investment Virtual Conference
September 10, 2020
Read Full Release
MaxCyte Appoints Amanda L. Murphy as Chief Financial Officer and Names Ron Holtz as Senior Vice President & Chief Accounting Officer
September 9, 2020
Read Full Release
CARMA Cell Therapies™ Expands Phase I Trial of Anti-Mesothelin mRNA CAR-PBMC Cell Therapy MCY-M11
August 18, 2020
Read Full Release
APEIRON Biologics and MaxCyte Enter into Clinical and Commercial Licensing Agreement for APN401
July 8, 2020
Read Full Release
MaxCyte’s CEO to Present Update on Life Sciences Business & First-in-class CARMA™ Cellular Therapies at BIO CEO & Investor Conference in New York
February 5, 2020
Read Full Release
2019
MaxCyte Appoints New Executive Vice President, Business Development for CARMA™ Cellular Therapies and Provides Clinical Trial Update
December 19, 2019
Read Full Release
MaxCyte and KSQ Therapeutics Announce Development and Commercialization Agreement to Enable the Advancement of KSQ’s Adoptive Cell Therapy Programs
December 4, 2019
Read Full Release
Vor Biopharma and MaxCyte Announce Clinical and Commercial License Agreement for Engineered Hematopoietic Stem Cells (eHSCs) to Treat Cancer
November 21, 2019
Read Full Release
MaxCyte to Present at BIO-Europe 2019
November 6, 2019
Read Full Release
MaxCyte Advances Phase I Clinical Trial of Lead CARMA™ mRNA-based Cell Therapy to Third Cohort of Patients
October 24, 2019
Read Full Release
MaxCyte Announces Presentations at 5th Annual Cell & Gene Therapy Congress Highlighting Unique Promise of Its Technology
October 23, 2019
Read Full Release
MaxCyte to Provide Updates on First-in-class CARMA™ Platform at BIO Investor Forum
October 15, 2019
Read Full Release
Editas Medicine and MaxCyte Announce Clinical and Commercial License Agreement for Engineered Cell Medicines
October 7, 2019
Read Full Release
MaxCyte to Present Updates on ExPERT™ Platform at Upcoming Conferences
October 2, 2019
Read Full Release
MaxCyte Presents Updates on First-in-class CARMA™ Platform at Upcoming Meetings
September 30, 2019
Read Full Release
MaxCyte Announces Presentation at ICLE 2019
September 9, 2019
Read Full Release
MaxCyte Adds Vice President, Non-Clinical and Translational Studies, to Support Advancement of Programs from Its CARMA™ Platform
July 23, 2019
Read Full Release
MaxCyte CEO Doug Doerfler to Present at 2019 BIO International Convention
May 29, 2019
Read Full Release
MaxCyte Progresses Phase I Clinical Trial of Lead mRNA-based Cell Therapy from its CARMA™ Platform
May 8, 2019
Read Full Release
MaxCyte Presents at 22nd Annual ASGCT Meeting on Manufacturing Process for First CARMA™ Drug Candidate, Including One-Day Cell Processing
May 1, 2019
Read Full Release
MaxCyte® Launches ExPERT™ Family of Instruments, Providing a Unifying Technology Platform from Concept to Commercialization for the Next Generation of Cellular Therapies
April 8, 2019
Read Full Release
New Processing Assemblies Deliver Increased Flexibility, Efficiency, and Ease of Cell Recovery
March 29, 2019
Read Full Release
NK Cells: The Latest Recruits in the Battle Against Cancer
March 29, 2019
Read Full Release
Don’t Settle for Just Your Average CHO and Other Cell Line Development Advances
March 29, 2019
Read Full Release
MaxCyte to Present on CARMA™ Platform at Two Upcoming Industry Conferences in Europe
March 18, 2019
Read Full Release
2018
MaxCyte to Present on Its CARMA™ Platform During Biotech Showcase™and Phacilitate: Leaders World/World Stem Cell Summit 2019
December 19, 2018
Read Full Release
MaxCyte to Present at Piper Jaffray 30th Annual Healthcare Conference
November 21, 2018
Read Full Release
Precision BioSciences and MaxCyte Enter into Clinical and Commercial License Agreement
November 14, 2018
Read Full Release
CRISPR Therapeutics and MaxCyte Expand Clinical and Commercial License Agreement into Oncology
November 9, 2018
Read Full Release
MaxCyte to Present on CARMA™ Platform at BIO-EUROPE®
October 30, 2018
Read Full Release
MaxCyte Commences Dosing in First Clinical Trial in Solid Tumors
October 10, 2018
Read Full Release
MaxCyte, Inc. to Present on CARMA™ Platform at Two Upcoming Industry Conferences
August 29, 2018
Read Full Release
MaxCyte Receives US FDA Investigational New Drug Clearance for First Clinical Program
July 16, 2018
Read Full Release
MaxCyte and U.S. National Institutes of Health’s National Heart, Lung, and Blood Institute Enter Cooperative Research & Development Agreement for Sickle Cell Disease
June 11, 2018
Read Full Release
MaxCyte, Inc. to Present at 2018 BIO International Convention
May 29, 2018
Read Full Release
MaxCyte Reports Preclinical Results at ASGCT Annual Meeting Showing Efficient Correction of Sickle Cell Mutation in Hematopoietic Stem Cells (HSC)
May 21, 2018
Read Full Release
MaxCyte Reports Preclinical Results at ASGCT Annual Meeting Showing Efficient Correction of Sickle Cell Mutation in Hematopoietic Stem Cells (HSC)
May 21, 2018
Read Full Release
MaxCyte Appoints Dr.Claudio Dansky Ullmann as Chief Medical Officer
April 25, 2018
Read Full Release
MaxCyte, Inc. to Present at BIO Europe and BIOCapital USA Conferences this Month
March 12, 2018
Read Full Release
Dr. Richard Douglas Joins MaxCyte Board
February 13, 2018
Read Full Release
MaxCyte, Inc. to Present at Two Life Sciences Conferences
January 2, 2018
Read Full Release
2017
MaxCyte, Inc. to Present at Phacilitate’s Cell & Gene Therapy Europe Conference
September 14, 2017
Read Full Release
MaxCyte Appoints Executive Vice President of Global Marketing
August 14, 2017
Read Full Release
MaxCyte and National Institute of Allergy and Infectious Diseases to Collaborate on Research for Ultra-Rare Disease Therapy
June 7, 2017
Read Full Release
MaxCyte, Inc. to Present Positive Preclinical Data for Sickle Cell Disease
April 25, 2017
Read Full Release
CRISPR Therapeutics and Casebia Therapeutics Announce Commercial License Agreement with Maxcyte
March 14, 2017
Read Full Release
MaxCyte to Present Pre-Clinical CARMA Data at AACR Meeting
March 2, 2017
Read Full Release
MaxCyte, Inc. to Present at Phacilitate Cell & Gene Therapy World Conference
January 16, 2017
Read Full Release
MaxCyte, NIH NIAID Study Published in Science Translational Medicine Demonstrates CRISPR-Cas9 Repair of X-linked Chronic Granulomatous Disease (CGD) Gene
January 12, 2017
Read Full Release
2016
2016
MaxCyte Announces Strategic Immuno-Oncology Collaboration to Advance New Generation of CAR-based Cell Therapies
December 21, 2016
Read Full Release
MaxCyte Appoints Executive Vice President, Business and Strategic Development
November 2, 2016
Read Full Release
MaxCyte, Inc. to Present at 2016 Cell & Gene Meeting on the Mesa and Biotech Week Boston 2016
September 29, 2016
Read Full Release
MaxCyte Bolsters Distributor Network in Asia to Meet Growing Market Demands for MaxCyte STX® and MaxCyte VLX® Transfection Systems
September 6, 2016
Read Full Release
